Erratum: MiRNA-708 Control of CD44+ prostate cancer-initiating cells (Cancer Research (2012) 72 (3618-3630) DOI: 10.1158/0008-5472.CAN-12-0540);MiRNA-708 control of CD44+ prostate cancer-initiating cells

Cancer Research

Volumn 72, Issue 14, 2012, Pages 3618-3630

  Saini, Sharanjot ^a   Majid, Shahana ^a   Shahryari, Varahram ^a   Arora, Sumit ^a   Yamamura, Soichiro ^a   Chang, Inik ^a   Zaman, Mohd Saif ^a   Deng, Guoren ^a   Tanaka, Yuichiro ^a   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; MICRORNA; MICRORNA 708; OLIGONUCLEOTIDE; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENICITY; CELL SUBPOPULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER INITIATING CELLS; PROTEIN TARGETING; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 84863921583     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-1130     Document Type: Erratum

References (41)

1. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000.
2. Brooks DD, Wolf A, Smith RA, Dash C, Guessous I. Prostate cancer screening 2010: updated recommendations from the American Cancer Society. J Natl Med Assoc 2010;102:423-9.
3. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98.
4. Grubb RL III, Kibel AS. Prostate cancer: screening, diagnosis and management in 2007. Mol Med 2007;104:408-13.
5. Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006;33:201-10.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
7. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14. (Pubitemid 46095228)
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51. (Pubitemid 41713363)
9. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008;68:1820-5. (Pubitemid 351416567)
10. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44 +prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.
11. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-19. (Pubitemid 40994406)
12. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:6796-805. (Pubitemid 47105527)
13. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 2011;17:5287-98.
14. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999;59:5030-6. (Pubitemid 29472911)
15. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8. (Pubitemid 27145681)
16. Li H, Jiang M, Honorio S, Patrawala L, Jeter CR, Calhoun-Davis T, et al. Methodologies in assaying prostate cancer stem cells. Methods Mol Biol 2009;568:85-138.
17. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
18. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, et al. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res 2011;71:2611-21.
19. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010;29:1580-7.
20. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
21. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008;36:D149-53. (Pubitemid 351149712)
22. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007;27:91-105. (Pubitemid 46991392)
23. Li H, Tang DG. Prostate cancer stem cells and their potential roles in metastasis. J Surg Oncol 2011;103:558-62.
24. Wicha MS. Stemming a tumor with a little miR. Nat Med 2011;17:162-4.
25. Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res 2010;3:1-7.
26. Liu C, Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res 2011;71:5950-4.
27. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500. (Pubitemid 40617277)
28. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98. (Pubitemid 38058492)
29. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89.
30. Ivanovska I, Cleary MA. Combinatorial microRNAs: working together to make a difference. Cell Cycle 2008;7:3137-42.
31. Yang K, Handorean AM, Iczkowski KA. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol 2009;2:361-9.
32. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008;455:64-71.
33. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58-63.
34. Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G, et al. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) 2011;4:1698-709.
35. Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA. Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 2009;23:2592-7.
36. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010;70:5147-54.
37. Valastyan S, Weinberg RA. MicroRNAs: crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle 2009;8:3506-12.
38. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6. (Pubitemid 39006542)
39. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
40. Sasaki T, Nakashiro K, Tanaka H, Azuma K, Goda H, Hara S, et al. Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2010;399:79-83.
41. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009;106:268-73.